Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Mechanisms of impaired differentiation in rhabdomyosarcoma.

Keller C, Guttridge DC.

FEBS J. 2013 Sep;280(17):4323-34. doi: 10.1111/febs.12421. Epub 2013 Jul 31. Review.

2.

Alveolar rhabdomyosarcoma-associated proteins PAX3/FOXO1A and PAX7/FOXO1A suppress the transcriptional activity of MyoD-target genes in muscle stem cells.

Calhabeu F, Hayashi S, Morgan JE, Relaix F, Zammit PS.

Oncogene. 2013 Jan 31;32(5):651-62. doi: 10.1038/onc.2012.73. Epub 2012 Jun 18.

PMID:
22710712
3.

Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma.

Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K, Shipley J, Hahn H, Fulda S.

Oncogene. 2010 Dec 2;29(48):6323-30. doi: 10.1038/onc.2010.368. Epub 2010 Sep 6.

PMID:
20818440
4.

FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.

Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC.

J Cell Biol. 2005 Sep 12;170(6):903-12. Retraction in: Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. J Cell Biol. 2007 May 7;177(3):563.

5.

PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.

Hanna JA, Garcia MR, Go JC, Finkelstein D, Kodali K, Pagala V, Wang X, Peng J, Hatley ME.

Cell Death Dis. 2016 Jun 9;7(6):e2256. doi: 10.1038/cddis.2016.159.

6.

Are myogenin and myoD1 expression specific for rhabdomyosarcoma? A study of 150 cases, with emphasis on spindle cell mimics.

Cessna MH, Zhou H, Perkins SL, Tripp SR, Layfield L, Daines C, Coffin CM.

Am J Surg Pathol. 2001 Sep;25(9):1150-7.

PMID:
11688574
8.

Molecular pathogenesis of rhabdomyosarcoma.

Xia SJ, Pressey JG, Barr FG.

Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104. Review.

PMID:
12170781
9.

SMYD1 and G6PD modulation are critical events for miR-206-mediated differentiation of rhabdomyosarcoma.

Coda DM, Lingua MF, Morena D, Foglizzo V, Bersani F, Ala U, Ponzetto C, Taulli R.

Cell Cycle. 2015;14(9):1389-402. doi: 10.1080/15384101.2015.1005993.

10.

The RhoE/ROCK/ARHGAP25 signaling pathway controls cell invasion by inhibition of Rac activity.

Thuault S, Comunale F, Hasna J, Fortier M, Planchon D, Elarouci N, De Reynies A, Bodin S, Blangy A, Gauthier-Rouvière C.

Mol Biol Cell. 2016 Sep 1;27(17):2653-61. doi: 10.1091/mbc.E16-01-0041. Epub 2016 Jul 13.

11.

Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.

Skrzypek K, Kusienicka A, Szewczyk B, Adamus T, Lukasiewicz E, Miekus K, Majka M.

Oncotarget. 2015 Oct 13;6(31):31378-98. doi: 10.18632/oncotarget.5145.

12.

Molecular classification of rhabdomyosarcoma--genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group.

Davicioni E, Anderson MJ, Finckenstein FG, Lynch JC, Qualman SJ, Shimada H, Schofield DE, Buckley JD, Meyer WH, Sorensen PH, Triche TJ.

Am J Pathol. 2009 Feb;174(2):550-64. doi: 10.2353/ajpath.2009.080631. Epub 2009 Jan 15.

13.

A rapid one-generation genetic screen in a Drosophila model to capture rhabdomyosarcoma effectors and therapeutic targets.

Galindo KA, Endicott TR, Avirneni-Vadlamudi U, Galindo RL.

G3 (Bethesda). 2014 Dec 9;5(2):205-17. doi: 10.1534/g3.114.015818.

14.

MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development.

Cieśla M, Dulak J, Józkowicz A.

Int J Biochem Cell Biol. 2014 Aug;53:482-92. doi: 10.1016/j.biocel.2014.05.003. Epub 2014 May 14. Review.

PMID:
24831881
15.

Epithelioid rhabdomyosarcoma: a clinicopathologic and molecular study.

Zin A, Bertorelle R, Dall'Igna P, Manzitti C, Gambini C, Bisogno G, Rosolen A, Alaggio R.

Am J Surg Pathol. 2014 Feb;38(2):273-8. doi: 10.1097/PAS.0000000000000105.

PMID:
24418861
16.

Detection of PAX3/PAX7-FKHR fusion transcripts in rhabdomyosarcoma and other small round cell tumors by 1-step reverse transcriptase polymerase chain reaction: a novel tool for diagnosis and differentiation.

Yang XL, Zhang SC, Zhang SW, Wang H.

Ann Diagn Pathol. 2012 Apr;16(2):107-11. doi: 10.1016/j.anndiagpath.2011.09.004. Epub 2011 Dec 24.

PMID:
22197543
17.

Rhabdomyosarcoma: molecular analysis of Igf2, MyoD1 and Myogenin expression.

Krskova L, Augustinakova A, Drahokoupilova E, Sumerauer D, Mudry P, Kodet R.

Neoplasma. 2011;58(5):415-23.

PMID:
21744995
18.

Update on molecular findings in rhabdomyosarcoma.

El Demellawy D, McGowan-Jordan J, de Nanassy J, Chernetsova E, Nasr A.

Pathology. 2017 Apr;49(3):238-246. doi: 10.1016/j.pathol.2016.12.345. Epub 2017 Feb 27. Review.

PMID:
28256213
19.

[Molecular mechanisms regulating metastasis of cancer cells with special emphasis on rhabdomyosarcoma].

Tarnowski M, Grymuła K, Tkacz M, Czerewaty M, Poniewierska-Baran A, Ratajczak MZ.

Postepy Hig Med Dosw (Online). 2014 Mar 7;68:258-70. Review. Polish.

20.

Muscle-specific gene expression in rhabdomyosarcomas and stages of human fetal skeletal muscle development.

Tonin PN, Scrable H, Shimada H, Cavenee WK.

Cancer Res. 1991 Oct 1;51(19):5100-6.

Supplemental Content

Support Center